SCHEMBL5583154

SCHEMBL5583154

COc1cccc(C2(O)CCN(C(=O)c3ccc4[nH]c5c(c4c3)CCCc3cn[nH]c3-5)CC2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 5/20 0.51
RIPK1 Q13546 4/20 0.51
LMNA P02545 3/20 0.50
ALDH1A1 P00352 4/20 0.46
PKLR P30613 1/20 0.44
KDR P35968 1/20 0.44
MAPT P10636 3/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
MPI P34949 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HTT P42858 1/20 0.40
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5583232 0.89 MAPK10 (0.53) MAPK10RIPK1LMNAALDH1A1KDR
SCHEMBL5583281 0.88 MAPK10 (0.48) MAPK10RIPK1LMNAALDH1A1PKLR
SCHEMBL5583124 0.88 MAPK10 (0.48) MAPK10RIPK1LMNAALDH1A1PKLR
SCHEMBL5583121 0.86 MAPK10 (0.51) MAPK10RIPK1LMNAALDH1A1PKLR
SCHEMBL5582988 0.86 ACACB (0.45) MAPK10RIPK1LMNAALDH1A1PKLR
SCHEMBL5582981 0.84 MAPK10 (0.45) MAPK10RIPK1LMNAALDH1A1KDR
SCHEMBL5583259 0.84 MAPK10 (0.51) MAPK10RIPK1LMNAALDH1A1KDR
SCHEMBL5583182 0.84 MAPK10 (0.51) MAPK10RIPK1LMNAALDH1A1PKLR
SCHEMBL14392011 0.84 MAPK10 (0.46) MAPK10RIPK1LMNAALDH1A1KDR
SCHEMBL5583184 0.84 PKLR (0.46) MAPK10RIPK1LMNAALDH1A1PKLR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US disclosed
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US disclosed
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer IGF1R, KDR, ERBB2 MAPK10 1222/4885RIPK1 702/4885LMNA 4288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.